Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men
and women. Antipsychotic induced sexual side effects may be a barrier to treatment
compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have
higher rates of causing prolactin elevations that may be implicated in sexual dysfunction.
The basic premise of this study is to identify patients who believe they have experienced
sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long
acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels.
Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience
Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine
if such a switch is helpful.